Cargando…

Novel mechanism of ghrelin therapy for cachexia

Detalles Bibliográficos
Autores principales:	Hatanaka, Michiyoshi, Konishi, Masaaki, Ishida, Junnichi, Saito, Masakazu, Springer, Jochen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670749/ https://www.ncbi.nlm.nih.gov/pubmed/26674390 http://dx.doi.org/10.1002/jcsm.12084

Ejemplares similares

Irisin – a myokine potentially bridging muscle and fat tissue in cachexia
por: Konishi, Masaaki, et al.
Publicado: (2015)

Single‐nucleotide polymorphisms in cachexia‐related genes: Can they optimize the treatment of cancer cachexia?
por: Ishida, Junichi, et al.
Publicado: (2017)

Hypermetabolism: should cancer types, pathological stages and races be considered in assessing metabolism and could elevated resting energy expenditure be the therapeutic target in patients with advanced cancer?
por: Ishida, Junichi, et al.
Publicado: (2015)

Concern regarding quality and quality of muscle
por: Saitoh, Masakazu, et al.
Publicado: (2015)

The concept that focuses on oral motor and feeding function in cancer patients with muscle wasting: Skeletal muscle mass is associated with severe dysphagia in cancer patients
por: Saitoh, Masakazu, et al.
Publicado: (2016)

Growth differentiation factor‐15 as a prognostic biomarker in cancer patients
por: Ishida, Junichi, et al.
Publicado: (2016)

Clinical perspective for wasting in diaphragm, an ever‐trained muscle
por: Konishi, Masaaki, et al.
Publicado: (2016)

Nutrition in cachexia: from bench to bedside
por: Konishi, Masaaki, et al.
Publicado: (2016)

Evidence for an effect of ACE inhibitors on cancer cachexia
por: Schanze, Nancy, et al.
Publicado: (2012)

Ghrelin for cachexia
por: Akamizu, Takashi, et al.
Publicado: (2010)

Cachexia research in Japan: facts and numbers on prevalence, incidence and clinical impact
por: Konishi, Masaaki, et al.
Publicado: (2016)

Bile acids for cachexia therapy: Reply to the letter by Shailendra Kapoor: Ursodeoxycholic acid and its emerging role in attenuation of tumor growth in gastrointestinal malignancies
por: Tschirner, Anika, et al.
Publicado: (2012)

Is cardiac wasting accompanied by skeletal muscle loss in breast cancer patients receiving anticancer treatment?
por: Ishida, Junichi, et al.
Publicado: (2017)

Considering technique of assessment and method for normalizing skeletal muscle mass
por: Saitoh, Masakazu, et al.
Publicado: (2017)

Physical activity for the prevention and treatment of sarcopenic obesity
por: Saitoh, Masakazu, et al.
Publicado: (2017)

Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment
por: Drescher, Cathleen, et al.
Publicado: (2015)

Chronic Renal Failure, Cachexia, and Ghrelin
por: Laviano, A., et al.
Publicado: (2010)

Open source in cachexia?
por: Stemmler, Britta, et al.
Publicado: (2015)

Does COVID‐19‐related cachexia mimic cancer‐related cachexia? Examining mechanisms, clinical biomarkers, and potential targets for clinical management
por: Kumar, Nagi B.
Publicado: (2021)

Febuxostat improves outcome in a rat model of cancer cachexia
por: Konishi, Masaaki, et al.
Publicado: (2015)

Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery
por: T. de Barros, Cecilia, et al.
Publicado: (2020)

Biomarkers and mechanisms associated with cancer‐induced cardiac cachexia: A systematic review
por: Bagnall, Lisa, et al.
Publicado: (2023)

Identification of Cause of Posttransplant Cachexia by PCR
por: Guitard, Joelle, et al.
Publicado: (2012)

Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia
por: Müller, Timo D., et al.
Publicado: (2010)

Rikkunshito, a ghrelin potentiator, ameliorates anorexia–cachexia syndrome
por: Fujitsuka, Naoki, et al.
Publicado: (2014)

Plasma Ghrelin Levels Are Associated with Anorexia but Not Cachexia in Patients with NSCLC
por: Blauwhoff-Buskermolen, Susanne, et al.
Publicado: (2017)

Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!
por: Thum, Thomas, et al.
Publicado: (2011)

Cardiac Cachexia - A Window to the Wasting Disorders
por: Coats, Andrew J Stewart
Publicado: (2018)

Anti‐cachexia therapy should target metabolism, inflammatory cytokines, and androgens in hormone‐independent cancers
por: Lambert, Charles Paul
Publicado: (2021)

Comment on 'Hand grip strength‐based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer' by Xie et al.
por: Ding, Ping'an, et al.
Publicado: (2023)

Potentiation of ghrelin signaling attenuates cancer anorexia–cachexia and prolongs survival
por: Fujitsuka, N, et al.
Publicado: (2011)

Natural ghrelin in advanced cancer patients with cachexia, a case series
por: Blum, David, et al.
Publicado: (2021)

Comment on “Metabolic Changes and Serum Ghrelin Level in Patients with Psoriasis”
por: Agilli, Mehmet, et al.
Publicado: (2015)

Receptor of ghrelin is expressed in cutaneous neurofibromas of individuals with neurofibromatosis 1
por: Rozza-de-Menezes, Rafaela E., et al.
Publicado: (2017)

Repurposing of approved cardiovascular drugs
por: Ishida, Junichi, et al.
Publicado: (2016)

Biomarkers for cancer cachexia: where do we stand?
por: Palus, Sandra, et al.
Publicado: (2020)

Quinolones Modulate Ghrelin Receptor Signaling: Potential for a Novel Small Molecule Scaffold in the Treatment of Cachexia
por: Torres-Fuentes, Cristina, et al.
Publicado: (2018)

In search of acute surgical stress biomarkers: Is ghrelin a potential candidate?
por: Kontoravdis, Nikolaos, et al.
Publicado: (2013)

Development of coated liposomes loaded with ghrelin for nose-to-brain delivery for the treatment of cachexia
por: Salade, Laurent, et al.
Publicado: (2017)

Cardiac cachexia: hic et nunc
por: Loncar, Goran, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h0j9m8h13jsvtm77b0umqhgm3c